Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 29;18(1):855.
doi: 10.1186/s12885-018-4756-0.

An in-silico study examining the induction of apoptosis by Cryptotanshinone in metastatic melanoma cell lines

Affiliations

An in-silico study examining the induction of apoptosis by Cryptotanshinone in metastatic melanoma cell lines

Radhika S Saraf et al. BMC Cancer. .

Abstract

Background: Metastatic melanoma is an aggressive form of skin cancer that evades various anti-cancer treatments including surgery, radio-,immuno- and chemo-therapy. TRAIL-induced apoptosis is a desirable method to treat melanoma since, unlike other treatments, it does not harm non-cancerous cells. The pro-inflammatory response to melanoma by nF κB and STAT3 pathways makes the cancer cells resist TRAIL-induced apoptosis. We show that due to to its dual action on DR5, a death receptor for TRAIL and on STAT3, Cryptotanshinone can be used to increase sensitivity to TRAIL.

Methods: The development of chemoresistance and invasive properties in melanoma cells involves several biological pathways. The key components of these pathways are represented as a Boolean network with multiple inputs and multiple outputs.

Results: The possible mutations in genes that can lead to cancer are captured by faults in the combinatorial circuit and the model is used to theoretically predict the effectiveness of Cryptotanshinone for inducing apoptosis in melanoma cell lines. This prediction is experimentally validated by showing that Cryptotanshinone can cause enhanced cell death in A375 melanoma cells.

Conclusion: The results presented in this paper facilitate a better understanding of melanoma drug resistance. Furthermore, this framework can be used to detect additional drug intervention points in the pathway that could amplify the action of Cryptotanshinone.

Keywords: Boolean networks; Cryptotanshinone; Melanoma; Stat3; Trail.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Color coding for gene interactions in Figs. 3 through 8
Fig. 2
Fig. 2
Legend for use in Figs. 3 through 8
Fig. 3
Fig. 3
Extrinsic Apoptosis and the nF κB pathways
Fig. 4
Fig. 4
JNK, p53, PI3K/AKT/mTOR and MAPK/ERK pathways
Fig. 5
Fig. 5
DNA damage pathway
Fig. 6
Fig. 6
Endoplasmic Reticulum Stress and the JNK pathway
Fig. 7
Fig. 7
STAT3 pathway
Fig. 8
Fig. 8
Mitochondrial Apoptosis Pathway
Fig. 9
Fig. 9
Boolean representation of the drug action countering a stuck-at-one fault
Fig. 10
Fig. 10
Boolean representation of the drug action countering a stuck-at-zero fault
Fig. 11
Fig. 11
Legend showing the color coding scheme used in Figs. 12, 13 and 14
Fig. 12
Fig. 12
Boolean network for the DNA Damage pathway
Fig. 13
Fig. 13
Boolean network for the TRAIL, ER Stress and STAT3 pathway
Fig. 14
Fig. 14
Boolean network for the PI3K/AKT/mTOR and MAPK/ERK pathway
Fig. 15
Fig. 15
Apoptosis ratios for different inputs
Fig. 16
Fig. 16
Apoptosis by CT in combination with a single drug in the presence of simultaneous occurrence of all faults
Fig. 17
Fig. 17
All possible combinations of faults and drugs when the input is TRAIL, with Cryptotanshinone
Fig. 18
Fig. 18
All possible combinations of faults and drugs when the input is TRAIL, without Cryptotanshinone
Fig. 19
Fig. 19
Experimental results for each single drug in combination with CT

Similar articles

Cited by

References

    1. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 2003;22:3138–51. doi: 10.1038/sj.onc.1206454. - DOI - PubMed
    1. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MRM, Yagita H. Nature’s TRAIL—On a Path to Cancer Immunotherapy. Immunity. 2003;18(1):1–6. doi: 10.1016/S1074-7613(02)00502-2. - DOI - PubMed
    1. Corazza N, Kassahn D, Jakob S, Badmann A, Brunner T. TRAIL-Induced Apoptosis: Between Tumor Therapy and Immunopathology. Ann N Y Acad Sci. 2009;1171:50–58. doi: 10.1111/j.1749-6632.2009.04905.x. - DOI - PubMed
    1. Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P. Cross resistance of melanoma to trail-induced apoptosis and chemotherapy. Update Cancer Ther. 2006;1(4):435–41. doi: 10.1016/j.uct.2006.08.004. - DOI
    1. Layek R, Datta A, Bittner M, Dougherty ER. Cancer therapy design based on pathway logic. Bioinformatics. 2011;27(4):548–55. doi: 10.1093/bioinformatics/btq703. - DOI - PubMed

MeSH terms

LinkOut - more resources